Furthermore, we found that lj-1-59 treatment significantly influences P21 (CDKN1A), PUMA (BBC3), GADD45A, PKMYT1, SESN2, MCM2, MCM3, MCM4 and MCM7 expression at the transcriptional level (Fig. 7d), which is consistent with the results in non-BRAFi-resistant melanoma cells, indicating that this compound has antitumor activity for melanoma treatment, regardless of BRAFi resistance. Here, MCM3 is linked to melanoma.